Biotech: Page 23
-
Stock via Getty Images
Another pandemic threat looms, and the antibacterial drug pipeline still isn't keeping up
A recent report from BIO details challenges in the antibiotic market — and new policy measures that could help.
By Kelly Bilodeau • March 23, 2022 -
Stock via Getty Images
Q&AWhy Astellas is adopting a 'focus area approach' to partnerships
Chief Strategy Officer, Naoki Okamura, explains why new trends and innovations require a different approach to alliances.
By Kim Ribbink • March 22, 2022 -
Explore the Trendline➔
Stock via Getty Images
TrendlineOncology
As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.
By PharmaVoice staff -
Stock via Getty Images
Psychedelics without the party: Inside MindMed's LSD makeover
MindMed’s CEO, Robert Barrow, on the company’s latest moves to ‘change the world’ with psychedelics.
By Alexandra Pecci • March 21, 2022 -
Retrieved from PharmaVOICE on March 21, 2022
Q&ABioMarin’s new global head of advocacy is tackling the holy grail of patient engagement
In her new role, Dr. Roz is keeping her patient-first approach.
By Taren Grom • March 21, 2022 -
Stock via Getty Images
Attralus' medical officer believes systemic amyloidosis could be 'solvable'
Gregory Bell is not just aiming to treat amyloidosis, but eventually cure it.
By Robin Robinson • March 18, 2022 -
Stock via Getty Images
COVID-19 trials aren't the only studies that can achieve super speed
Is it possible to enroll clinical trials 10 times faster than the industry’s average speed? Elligo Health Research thinks so.
By Kelly Bilodeau • March 15, 2022 -
Image courtesy of Medigene.
Q&AMedigene's CEO on striking a collaboration deal with BioNTech
The two companies recently announced a $29 million collaboration.
By Jared Whitlock • March 15, 2022 -
Permission granted by Sanjeev Luther.
Q&AClearing hurdles in rare cancer drug development
Rafael’s CEO, Sanjeev Luther, explains why flexibility and agility are keys to success in the rare cancer space.
By Kim Ribbink • March 14, 2022 -
Stock via Getty Images
Q&A // Biotech SpotlightLiquid biopsy is a multibillion-dollar market, and InterVenn is looking to take advantage
The company’s CEO explains how its liquid biopsy tests target a unique, untapped layer of biology.
By Taren Grom • March 14, 2022 -
Permission granted by Terry Weber
Q&ABiote CEO: Employers need to normalize women's health issues in the workforce
A survey by Biote reveals the impact of menopause on working women.
By Robin Robinson • March 14, 2022 -
Image courtesy of Ultragenyx.
Q&AUltragenyx's CEO on building a 'next-gen' rare disease company
How Dr. Emil Kakkis is maintaining the soul of a startup while undergoing growth.
By Kim Ribbink • March 9, 2022 -
Permission granted by Russell Potterfield.
ProfileFrom angel to operator: The unlikely journey of Endevica Bio's CEO
Russell Potterfield is honing his new found passion for the space to guide Endevica into the clinic.
By Jared Whitlock • March 9, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Genentech's Quita Highsmith
Quita Highsmith is changing how Genentech approaches diversity and inclusion across the board — from drug development to career advancement.
By Taren Grom • March 9, 2022 -
Stock via Getty Images
ProfileHorizon’s VP of R&D on her ascent in biotech — and bringing other female scientists along for the ride
Elizabeth Thompson is guiding Horizon through new drug approvals while leading the way for young women in STEM.
By Alexandra Pecci • March 8, 2022 -
Stock via Getty Images
Two key factors behind NYC's record-setting rise in healthcare funding
According to a new report, women’s and digital health led to an explosion in funding last year in NYC.
By Robin Robinson • March 7, 2022 -
Stock via Getty Images
Are patients happy? This simple question could shake up clinical trials
The migration to DCTs is helping uncover critical gaps in patient experience.
By Kelly Bilodeau • March 4, 2022 -
Permission granted by Andrew Hopkins.
Q&AExscientia scored the largest AI deal with a Big Pharma to date — but it's just getting started
The company’s CEO on the road ahead for AI capabilities in pharma.
By Meagan Parrish • March 4, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Lyndra Therapeutics' CEO Dr. Trish Hurter
With Lyndra's ultra-long-acting therapies, Hurter and the company are aiming to reinvent medicines.
By Taren Grom • March 2, 2022 -
Diego Camargo/PharmaVoice
The 2022 PharmaVoice 100 — new look, same drive for excellence
Some of the industry’s biggest names have been on our list of honorees. Now it’s time to find this year’s inspiring leaders.
By Taren Grom • Feb. 28, 2022 -
Stock via Getty Images
Q&ACandel's CEO looks to help ignite a new era of cancer treatments
Candel Therapeutics is advancing a next-gen approach in oncology: using viruses to kill cancer cells at the site of injection.
By Taren Grom • Feb. 28, 2022 -
Stock via Getty Images
Q&AWhy plasma derived therapies have a unique edge in rare diseases
Takeda's head of PDT R&D explains how the Japanese drug giant is advancing these emerging treatments.
By Kim Ribbink • Feb. 25, 2022 -
Permission granted by Guadalupe Hayes-Mota
ProfileGuadalupe Hayes-Mota's 'recipe' for tackling pharma's supply chain issues
A quest to expand access to medical treatment globally led to a new career path when Guadalupe Hayes-Mota left his biotech leadership roles to start his own company.
By Robin Robinson • Feb. 25, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Sumitovant's Chief Business Development and Commercial Officer Adele Gulfo
Adele Gulfo, chief business development and commercial officer at Sumitovant Biopharma, is leaning into her decades of experience to bring a future-focused approach to drug development.
By Taren Grom • Feb. 23, 2022 -
Stock via Getty Images
Eisai's mission to shake off Aduhelm's shadow and bring another AD drug to market
The company's senior VP of clinical research on how they're building off the science of Aduhelm to develop better Alzheimer's treatments.
By Kelly Bilodeau • Feb. 23, 2022 -
Stock via Getty Images
ProfileHow Veru is developing blockbuster drugs while avoiding biotech's 'valley of death'
Why sexual health and telemedicine are key to the company's goals in oncology.
By Meagan Parrish • Feb. 16, 2022
Previous
